X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PIRAMAL ENTERPRISES GSK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 61.1 7.8 780.6% View Chart
P/BV x 11.4 1.4 815.1% View Chart
Dividend Yield % 2.5 1.2 216.7%  

Financials

 GSK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-18
GSK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs2,7603,083 89.5%   
Low Rs2,0401,902 107.3%   
Sales per share (Unadj.) Rs339.0589.7 57.5%  
Earnings per share (Unadj.) Rs41.4284.0 14.6%  
Cash flow per share (Unadj.) Rs45.9310.5 14.8%  
Dividends per share (Unadj.) Rs35.0025.00 140.0%  
Dividend yield (eoy) %1.51.0 145.4%  
Book value per share (Unadj.) Rs242.91,467.0 16.6%  
Shares outstanding (eoy) m84.70180.27 47.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x7.14.2 167.5%   
Avg P/E ratio x57.98.8 660.3%  
P/CF ratio (eoy) x52.38.0 651.3%  
Price / Book Value ratio x9.91.7 581.5%  
Dividend payout %84.58.8 960.1%   
Avg Mkt Cap Rs m203,280449,332 45.2%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m5,23419,881 26.3%   
Avg. sales/employee Rs ThNM15,535.6-  
Avg. wages/employee Rs ThNM2,905.4-  
Avg. net profit/employee Rs ThNM7,482.5-  
INCOME DATA
Net Sales Rs m28,715106,310 27.0%  
Other income Rs m5452,595 21.0%   
Total revenues Rs m29,260108,906 26.9%   
Gross profit Rs m5,05951,599 9.8%  
Depreciation Rs m3804,773 8.0%   
Interest Rs m229,783 0.0%   
Profit before tax Rs m5,22219,638 26.6%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892-28,764 -6.6%   
Profit after tax Rs m3,50851,203 6.9%  
Gross profit margin %17.648.5 36.3%  
Effective tax rate %36.2-146.5 -24.7%   
Net profit margin %12.248.2 25.4%  
BALANCE SHEET DATA
Current assets Rs m21,815118,154 18.5%   
Current liabilities Rs m15,999462,260 3.5%   
Net working cap to sales %20.3-323.7 -6.3%  
Current ratio x1.40.3 533.5%  
Inventory Days Days6427 239.3%  
Debtors Days Days1947 40.2%  
Net fixed assets Rs m12,475113,727 11.0%   
Share capital Rs m847361 235.0%   
"Free" reserves Rs m19,726264,093 7.5%   
Net worth Rs m20,573264,454 7.8%   
Long term debt Rs m6242,206 0.0%   
Total assets Rs m39,475726,834 5.4%  
Interest coverage x2,612.01.7 157,410.1%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.70.1 497.3%   
Return on assets %8.911.1 79.8%  
Return on equity %17.119.4 88.1%  
Return on capital %26.210.3 254.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56415,110 3.7%   
Fx outflow Rs m7,4294,298 172.9%   
Net fx Rs m-6,86510,813 -63.5%   
CASH FLOW
From Operations Rs m4,728-159,666 -3.0%  
From Investments Rs m-1,042-17,677 5.9%  
From Financial Activity Rs m-3,066186,503 -1.6%  
Net Cashflow Rs m6209,364 6.6%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 4.0 255.0%  
FIIs % 23.8 26.6 89.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 16.5 93.3%  
Shareholders   102,036 93,274 109.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  AJANTA PHARMA  UNICHEM LAB  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY19); Net Profit Up 59.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 59.3% YoY). Sales on the other hand came in at Rs 31 bn (up 24.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Dec 12, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS